"Pursuant to the partnership, the company’s part
Post# of 36537
(Total Views: 322)
Posted On: 04/27/2021 10:37:45 AM
"Pursuant to the partnership, the company’s partners in China are responsible for the development and regulatory approval of the Ii-Key COVID Vaccine by the NMPA in China. All clinical trials will be conducted under guidelines of the International Council on Harmonisation (ICH), so the data can be used for submission to FDA, EMEA, and other international regulatory agencies; Generex Biotechnology Corporation and NuGenerex Immuno-Oncology maintain the rights to the Ii-Key-SARS-CoV-2 Vaccine in the rest of the world outside China"..
I understood that Gnbt renounces vaccine rights in China, but in exchange the Chinese carry on the so-called "accelerated" studies that can also be used for Fda and EMEA and other government agencies: at first glance, it seems positive to me.
Basically, the costs of the studies will be borne by the Chinese partners for China, and can also be used for government agencies in the rest of the world, including the FDA.
Did I misinterpret?
I understood that Gnbt renounces vaccine rights in China, but in exchange the Chinese carry on the so-called "accelerated" studies that can also be used for Fda and EMEA and other government agencies: at first glance, it seems positive to me.
Basically, the costs of the studies will be borne by the Chinese partners for China, and can also be used for government agencies in the rest of the world, including the FDA.
Did I misinterpret?
(1)
(1)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼